Background: Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited treatment options. Gemcitabine provides a marginal survival benefit for patients with advanced PDAC. Dasatinib is a competitive inhibitor of Src kinase, which is overexpressed in PDAC tumors. Dasatinib and gemcitabine were combined in a phase 1 clinical trial where stable disease was achieved in two of eight patients with gemcitabine-refractory PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion and early metastases. Overall survival remains poor in patients with inoperable, locally advanced, or metastatic PDAC. Gemcitabine remains one therapeutic option for patients with advanced PDAC and provides a marginal survival advantage [1, 2] . Among other therapeutic options, two combination regimens have further extended survival prolongation of gemcitabine [3, 4] . Chemoradiation may increase locoregional control in PDAC (at the cost of considerable toxicity), but this approach does not address the principal mode of treatment failure in locally advanced PDAC, which is development of distant metastases.
Src-family kinases are non-receptor tyrosine kinases with a critical role in cellular proliferation [5] [6] [7] . Src is involved in many aspects of tumor cell behavior that influence metastatic capacity, such as survival, adhesion, migration, and invasion. Furthermore, Src is over-expressed in PDAC [8, 9] . Compared with normal pancreatic ducts, increased expression and activation of Src were observed in 74% and 60% of tumors, respectively, correlating with reduced survival in resected PDAC [10] . Moreover, gemcitabine chemo-resistance in PDAC cell lines was associated with increased Src kinase activity [11] . Src kinase inhibition enhances gemcitabine-induced cytotoxicity in vitro, and significantly increases tumor growth inhibition in orthotopic models in vivo in combination with gemcitabine compared to either agent alone [11] .
Dasatinib, a competitive inhibitor of Src and Abl kinases [12, 13] , represents an effective therapy for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [14] [15] [16] [17] [18] . Treatment of pancreatic cancer cell lines in vitro with dasatinib inhibits invasion and migration at concentrations that inhibit Src kinase activity [10, 19] , as well as proliferation and anchorage-independent cell growth [19, 20] . Dasatinib inhibits pancreatic tumor growth in vivo in xenograft models [19, 20] and inhibits the development of metastases in vivo in a genetically engineered mouse model of pancreatic cancer [10] , suggesting that this agent might best be used in patients without metastatic disease to prevent development of distant metastases. Unpublished data from the first author's laboratory suggests that there was a trend to improved overall survival with the combination of gemcitabine and dasatinib compared to dasatinib alone in a genetically engineered mouse model of pancreatic cancer that did not reach statistical significance (P ¼ 0.08).
Dasatinib and gemcitabine were combined in two phase 1 clinical trials. In the first study, recommended combination doses were dasatinib 100 mg by mouth (PO) daily and gemcitabine 600 mg/m 2 intravenously (IV) weekly for the first 7 of 8 weeks, and dose limiting toxicities included fatigue and dehydration [21] . Stable disease was achieved in two of eight patients with gemcitabine-refractory PDAC. In a second phase 1 combination trial, recommended combination doses were dasatinib 100 mg daily by mouth, and gemcitabine 1000 mg/m 2 for 3 weeks out of 4 and dose-limiting toxicities included neutropenia with infection, elevation of ALT, and pneumonitis [22] . The current phase 2 clinical trial compared the combination of gemcitabine plus dasatinib to gemcitabine plus placebo in patients with locally advanced, non-metastatic PDAC. The primary objective was overall survival (OS), with comparison of safety and progression-free survival (PFS) as secondary objectives. Exploratory objectives included freedom from distant metastases (FFDM), pain, fatigue, CA19-9 response rates, and objective responses.
Patients and methods

Patients
This placebo-controlled, randomized, double-blind, multi-center, phase II study was conducted in accordance with Good Clinical Practice (GCP) guidelines and approved by the research ethics committees at each of the participating institutions. All patients provided written, informed consent prior to undergoing any study-related procedures.
Eligible patients had pathologically proven PDAC with unresectable disease due to local extension, invasion, or lymph node involvement beyond the surgical field but had no evidence of metastatic disease based on imaging assessments. Additional eligibility criteria are included in sup plementary information, available at Annals of Oncology online.
Study design
Patients were randomized 1:1 to receive gemcitabine 1000 mg/m 2 (30-min IV infusion) on days 1, 8, and 15 of a 28-day cycle combined with either 100 mg oral dasatinib (dasatinib group) or placebo tablets (placebo group) daily with breakfast ( Figure 1 ). Stratification factors included baseline ECOG PS of 0 versus 1 and intent to administer radiotherapy (yes/no). At the investigator's discretion, patients without evidence of metastatic disease after six cycles of treatment had the option to receive radiotherapy with conventional fractionation with or without concomitant 5-FU or capecitabine chemotherapy starting within 3 weeks of cycle 6 study therapy. Gemcitabine and dasatinib/placebo were interrupted during radiotherapy and resumed within 6 weeks after radiotherapy completion. Study treatment continued until progressive disease (PD), withdrawal of consent, or unacceptable toxicity.
Dose delays and dose modifications were based on observed toxicities (supplementary methods Tables S1-S3, available at Annals of Oncology online) and subsequent treatment is described in supplementary information, available at Annals of Oncology online.
Evaluations and response assessment
Pre-treatment evaluation included a complete history and physical examination, vital signs, assessment of PS, blood counts, biochemical profile, coagulation screen, electrocardiograms, serum CA19-9 analysis, urinalysis, pregnancy test (if appropriate), and assessment of pain and fatigue (10-point numeric scales). Toxicity was graded using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) Version 3.0.
Radiologic studies to evaluate disease sites were performed within 14 days prior to dosing on day 1, and every 8 weeks until disease progression, determined by RECIST v1.1 [23] . Other assessments are included in sup plementary information, available at Annals of Oncology online.
Statistical hypothesis and analyses
All analyses were performed on an intent-to-treat basis. OS was determined from the date of randomization until death (any cause) and analyzed by the log rank method. Hazard ratio was estimated using the Cox proportional hazards model with the following predictors: treatment, baseline ECOG, geographical region, CA19-9, and whether radiotherapy was received during the trial. A sample size of 200 patients was sufficient to demonstrate an increase in median OS from 10 to 13.3 months (Hazard Ratio [HR] ¼ 0.75) with 79% power using a 1-sided a of 0.2. This sample size would have 88% power to detect an increase in PFS from 5 to 7 months (HR ¼ 0.714; 1 sided a ¼ 0.15).
PFS was defined as the time from randomization until local or distant disease progression (RECIST v1.1). Additional analyses are included in the supplementary information, available at Annals of Oncology online.
Results
Patients
A total of 280 patients were screened, and 202 patients were enrolled at 79 trial sites in 15 countries in Australasia, Europe, and North America (Figure 2 ). Intent-to-treat groups for analysis consisted of 100 patients assigned to receive gemcitabine plus dasatinib (dasatinib group) and 102 assigned to receive gemcitabine plus placebo (placebo group). Three patients, two in the dasatinib group and one in the placebo group, did not receive study treatment and were not included in safety analyses.
Median age of enrolled patients was 65 years (range 37-87), and 51% were male (Table 1) . A higher proportion of patients were male in the dasatinib arm (57% versus 45%). ECOG PS was GEM, gemcitabine. a. Patients continued to receive trial treatment until disease progression, unacceptable toxicity, withdrawal of consent, or trial termination and were discontinued from trial treatment for disease progression when new cancer lesions were detected outside the loco-regional area (eg, in lung or liver) or when unequivocal evidence of local cancer progression was observed. patients were followed for survival following cessation of trial therapy.
b. Radiotherapy performed at investigator's discretion for patients who showed no evidence of metastasis, beginning after cycle 6 with trial treatment dosing interruption. evenly distributed between groups with approximately 61% of patients in each group having a score of 1. Other prognostic factors were balanced, except that more patients in the dasatinib group had stage II disease (75% versus 68%). Median treatment duration of treatment with dasatinib or placebo was 4 and 5 cycles, respectively. Dose reduction of dasatinib was required in 34% of patients, and of placebo in 23% of patients. Median gemcitabine treatment duration was five cycles in both dasatinib and placebo groups. Dose reduction of gemcitabine was required in 42% of patients in each of the two groups. Radiotherapy was administered in 37 patients (18, dasatinib group; 19, placebo group), and more than 90% of the planned radiotherapy dose was administered in 34 patients. Concomitant chemotherapy was administered in 31 patients (12, dasatinib; 19, placebo) , and more than 90% of the planned radio-sensitizing chemotherapy was administered in 27 patients.
Efficacy analyses
At the data cut-off date of December 2, 2013, there was no significant difference in OS between the dasatinib and placebo groups (375 days versus 393 days, HR ¼ 1.16; 95% confidence interval Figure 3A, Table 2 ). There was also no significant difference in the median PFS of 167 and 166 days for dasatinib-and placebo-treated patients, respectively (HR ¼ 1.03; 95% CI: 0.76-1.39; P ¼ 0.8731) ( Figure 3B) . Additionally, in a population exclusive of patients with treatment discontinuation for reasons other than disease progression, median PFS was 221 and 218 days for dasatinib-and placebo-treated patients, respectively (HR ¼ 0.99; 95% CI: 0.68-1.43; P ¼ 0.7058).
Overall response rates were 11% in the dasatinib group and 8% in the placebo-treated group (P ¼ 0.4392) ( Table 2 ). No statistical difference was observed in other exploratory endpoints, including FFDM, pain progression, pain response, fatigue response, and CA19-9 response rates. A statistically non-significant difference was observed in median FFDM at 310 days for dasatinib-(n ¼ 32/99) and 380 days for placebo-(n ¼ 32/102) treated patients (P ¼ 0.7994). There was no difference in the CA 19-9 response.
Safety analysis
Treatment-emergent adverse events (TEAEs) of any cause occurred in 99% and 98% of patients in dasatinib and placebo groups, respectively (Table 3 ). In the dasatinib group, TEAEs Grade 3 occurring in 10% of patients include neutropenia (33% of patients), fatigue (16%), thrombocytopenia (13%), anemia (12%), and abdominal pain (10%); in the placebo group, they include neutropenia (26%) and thrombocytopenia (11%). Potential treatment-related AEs were more common in the dasatinib group (79% versus 64% of patients) (See supplemental results Table S4 , available at Annals of Oncology online). Overall, 31 patients (32%) in the dasatinib group discontinued treatment due to an AE versus 25 patients (25%) in the placebo group. The most common TEAEs leading to treatment discontinuation in dasatinib and placebo groups include pleural effusion (2 and 2 patients), peripheral edema (2 and 1), and vomiting (2 and 0), respectively.
Cardiopulmonary events have been noted for drugs in this class. No QT prolongation or ventricular arrhythmia events were reported. Hemorrhage, cardiac disorders, thromboembolic events, and pulmonary arterial hypertension were infrequent. Myelosuppression was frequent, occurring more within the dasatinib group (52% versus 29%). Fluid retention also occurred frequently, with both peripheral edema and pleural effusions being more common in the dasatinib group (34% versus 21% and 27% versus 7%, respectively). Additional safety analyses are included in the supplementary information, available at Annals of Oncology online.
Discussion
In vitro and in vivo studies support a role for dasatinib in inhibiting the development of metastases in PDAC. Dasatinib decreases cell proliferation, cell cycle progression, anchorage independent growth, migration, and invasion in PDAC cell lines in vitro [10, 19] and significantly inhibited the development of metastases in vivo with no effect on overall survival, probably due to progression of the primary tumor. Thus, there is evidence to support the hypothesis that Src kinase inhibitors may function as anti- metastatic agents in PDAC [10] . Consequently, this study was designed to determine if dasatinib could inhibit the development of metastases and improve overall survival if the growth of the primary tumor could be adequately controlled by gemcitabine in patients with inoperable, locally advanced, non-metastatic PDAC. Combined chemotherapy and radiotherapy could be administered (intention to treat prior to randomization) at the investigator's discretion to maximize recruitment across international sites in some of which chemo-radiation was standard of care for this patient population. Our study was closed to recruitment prior to the first presentation of the LAP-07 study [24] . Nevertheless, the hypothesis of our study was that the addition of dasatinib would inhibit the development of metastases, thereby improving survival, if local disease control was optimized. The combination of chemotherapy and radiotherapy may still have a role in optimizing local control, even if the results of the LAP 07 study suggests that this does not lead to a survival benefit. Addition of dasatinib to gemcitabine did not improve overall survival of patients with locally-advanced pancreatic cancer in this study versus placebo in combination with gemcitabine. Secondary and exploratory endpoint analyses, including PFS, overall response rate, FFDM, pain progression and response rate, fatigue progression and response rate, and CA19-9 response rate also showed no statistically significant differences between the two groups. Observed toxicities were consistent with the known safety profiles of dasatinib and gemcitabine in patients with solid tumors and revealed no new safety concerns [13, 21, 25] .
Several possible explanations account for the lack of a survival benefit in this study. First, recommended doses from the phase I study were dasatinib 100 mg PO daily and gemcitabine 600 mg/m 2 IV weekly for 7 of the first 8 weeks [21] . We used a higher dose of gemcitabine (1000 mg/m 2 on days 1, 8, 15 of a 28-day cycle) as we were concerned that a dose of 600 mg/m 2 IV weekly would be sub-therapeutic as first-line therapy of patients with PDAC when combined with a placebo in this double-blind study. Patients treated with 1000 mg/m 2 of gemcitabine in combination with dasatinib had a higher incidence of Grade 3 TEAEs, as well as of TEAEs that led to treatment discontinuation. In addition, fewer patients in the dasatinib group completed dosing cycles for both dasatinib and gemcitabine treatment compared with the placebo group. Therefore, it may be that because this combination was not well tolerated, administration of adequate chemotherapy for control of the primary tumor and of dasatinib to inhibit development of metastases may have been compromised. Data on subsequent treatments administered was not routinely collected after disease progression, a trial-specific endpoint for treatment discontinuation, was met. However, we think it is unlikely that any imbalance in second-line treatments between the two treatment arms will have obscured any significant difference in overall survival in the absence of any significant difference in progression-free survival with study therapy, especially given the modest, if any, survival benefit with second-line therapy in this disease at the time that the study was conducted.
Newer combination chemotherapy regimens, such as FOLFIRINOX, generate higher objective response rates and disease control in patients with metastatic disease. A more appropriate future study design to test the hypothesis that dasatinib inhibits the development of metastases may be to administer dasatinib as "maintenance" therapy, sequentially rather than in combination, after optimal control of localized non-metastatic disease with this more active chemotherapy regimen. For example, maintenance treatment with sunitinib in pancreatic adenocarcinoma may have inhibited the development of metastases and improved 2-year survival [26] . Alternatively, it may be more appropriate to evaluate dasatinib as a post-operative adjuvant treatment to improve overall survival by inhibiting metastases [2] . Although we enrolled patients without clinically or radiologically visible metastases in our study, it is possible that sub-clinical metastases were already present. Dasatinib may be more effective at inhibiting presumed micro-metastatic disease following potentially curative resection.
There is little evidence to support that Src pathway activation is a predictive marker for dasatinib activity. Given the paucity of archival tumor material that is invariably available for patients with inoperable, non-metastatic pancreatic cancer, and the lack of a robust predictive marker hypothesis, we did not think it justified to pursue mandatory additional pre-treatment tumor biopsies for exploratory research in this study. (5) 13 (13) 7 (7) 21 (11) 12 ( In conclusion, addition of dasatinib to gemcitabine failed to increase OS or PFS in patients with locally-advanced PDAC. Because this trial did not include pharmacodynamics, it is not possible to conclude whether dasatinib penetration of the tumor was adequate to inhibit tumoral Src. Conversely, the dasatinibgemcitabine combination generated increased toxicity relative to gemcitabine alone. This toxicity burden led to earlier discontinuation of combination therapy and likely contributed to the failure to improve OS. Alternative clinical trial designs with other drug combinations or sequenced schedules of administration could be pursued to further define a role for Src inhibition in PDAC treatment via metastasis inhibition.
